"Camptothecin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
| Descriptor ID |
D002166
|
| MeSH Number(s) |
D03.132.151
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Camptothecin".
Below are MeSH descriptors whose meaning is more specific than "Camptothecin".
This graph shows the total number of publications written about "Camptothecin" by people in this website by year, and whether "Camptothecin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 3 | 1 | 4 |
| 1996 | 7 | 1 | 8 |
| 1997 | 2 | 0 | 2 |
| 1998 | 5 | 2 | 7 |
| 1999 | 3 | 0 | 3 |
| 2000 | 9 | 2 | 11 |
| 2001 | 6 | 2 | 8 |
| 2002 | 13 | 2 | 15 |
| 2003 | 17 | 1 | 18 |
| 2004 | 14 | 2 | 16 |
| 2005 | 6 | 6 | 12 |
| 2006 | 9 | 11 | 20 |
| 2007 | 4 | 4 | 8 |
| 2008 | 6 | 9 | 15 |
| 2009 | 5 | 10 | 15 |
| 2010 | 4 | 9 | 13 |
| 2011 | 2 | 7 | 9 |
| 2012 | 4 | 5 | 9 |
| 2013 | 7 | 7 | 14 |
| 2014 | 1 | 8 | 9 |
| 2015 | 4 | 2 | 6 |
| 2016 | 4 | 4 | 8 |
| 2017 | 2 | 8 | 10 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 2 | 5 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 3 | 4 |
| 2023 | 2 | 3 | 5 |
| 2024 | 2 | 9 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Camptothecin" by people in Profiles.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25; 15(1):10213.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov; 41(11):4125-4139.
-
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):236.
-
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2024 08 09; 8:CD012757.
-
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep; 25(9):1147-1162.
-
Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression. JCO Precis Oncol. 2024 Jun; 8:e2300686.
-
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024 Jun; 25(6):707-719.
-
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 01; 42(19):2281-2294.
-
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clin Colorectal Cancer. 2024 Jun; 23(2):118-127.e6.